AIM-HIV PROJECT------------------------Instituto Salud Carlos III

Research frame

1. Industry-Academia collaboration.

Seprox Biotech is a biotechnology company specialized in the synthesis and production of chemical compounds. Seprox and ISCIII colaborates since 2010.

2. Collaborative effort of excellence laboratories highly specialized in different areas.

CEA will provide its expertise in animal models.
Universitá Vitá Salute-San Rafaelle are experts in antiinflammatory mechanisms.
ISCIII is a leading group in HIV pathogenesis.

3. EU support.

ISCIII, San Rafaelle and CEA are also funded with other European projects as CHAARM.

4. Future projection in developing countries.

The use of microbicides will be of high impact in developing countries especially sub-Saharan Africa.

NEWS 01  


Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of menstrual cycle. Read more.    




10/01/2014. The partners of the project and the Scientific Advisory Board attended the Progress Meeting of the project in Madrid.  



October 7-10, 2013. ISCIII and SEPROX presented an oral communication and a poster in the AIDS Vaccine Conference. Read more.


Instituto de Salud Carlos III. 2013. All rights reserved

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 305938.

Web Map  Legal AdviceAccesibility | Contact

cea unisr seprox biotech IscIII